RizLab Health — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

RizLab Health is a private, pre-revenue diagnostics company spun out from Rutgers University in 2018 (incorporated 2020), headquartered in Princeton, New Jersey. The company is commercializing the CytoTracker, a portable, handheld analyzer designed to provide rapid white blood cell (WBC) counts and differentials at the point of care, primarily targeting hospital emergency departments. By moving this critical test out of the central lab, RizLab seeks to address dangerous delays in infection assessment, support antibiotic stewardship, and improve patient flow. Its technology combines proprietary microfluidics with AI-powered software for cell quantification and potential viral/bacterial discrimination.

Infectious Disease

Technology Platform

Handheld diagnostic device combining proprietary microfluidics for blood sample processing with AI-powered software for white blood cell quantification and viral/bacterial discrimination.

Opportunities

The urgent need for faster infection triage in overcrowded emergency departments creates a large addressable market.

The platform's portability also opens opportunities in resource-limited settings, such as urgent care clinics, ambulances, and developing countries, where central lab access is constrained.

Risk Factors

Key risks include failure to obtain FDA clearance, particularly for the AI-based viral/bacterial discrimination claim, and the challenge of displacing entrenched central lab workflows.

As a single-product, pre-revenue company, it also faces significant financial and execution risk in scaling from pilots to commercialization.

Competitive Landscape

RizLab competes with large, established central lab hematology analyzer companies (e.g., Sysmex, Beckman Coulter) and emerging point-of-care testing players. Its differentiation hinges on the combination of portability, speed (<6 mins), and AI-driven interpretive guidance, but it must prove clinical utility and cost-effectiveness to gain market share.

More companies in Diagnostics & Precision Medicine →More companies in United States →